Increased pulmonary clearance of aerosolized 99Tcm-DTPA in patients with a subset of stage I sarcoidosis.
Measurement of the pulmonary clearance of aerosolized 99Tcm-diethylenetriamine pentaacetate (99Tcm-DTPA) as a marker of pulmonary parenchymal damage was performed in 10 non-smokers with sarcoidosis, none of whom was on medication, and the results compared with 12 normal controls. Posterior images were obtained using a single-headed gamma camera, with the subjects in a supine position, for 30 min after inhalation of aerosolized 99Tcm-DTPA had ceased. The pulmonary clearance of 99Tcm-DTPA was significantly increased in the sarcoidosis patients (57.6 +/- 22.1 min in the right lung, 62.2 +/- 22.7 min in the left lung) compared with the controls (79.3 +/- 10.2 and 78.4 +/- 7.7 min in the right and left lungs, respectively) (P < 0.05). Six of the 10 patients with sarcoidosis showed levels of pulmonary clearance, in both the right and left lungs, below the 95.5% confidence limit (mean +/- 2 S.D.) for the controls. Increased pulmonary clearance of 99Tcm-DTPA was also found in 2 of 4 patients with stage I sarcoidosis. No relationship was found between the pulmonary clearance of 99Tcm-DPTA and inflammatory markers (ACE, lysozyme) in the serum.
Watanabe
N
N
Department of Nuclear Medicine, Gunma University School of Medicine, Japan.
Inoue
T
T
Oriuchi
N
N
Suzuki
H
H
Hirano
T
T
Endo
K
K
D000328:Adult; D000336:Aerosols; D000368:Aged; D005260:Female; D006801:Humans; D007700:Kinetics; D008168:Lung / Q000000981:diagnostic imaging* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009113:Muramidase / Q000097:blood; D011877:Radionuclide Imaging; D012016:Reference Values; D012507:Sarcoidosis / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D016284:Technetium Tc 99m Pentetate / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013997:Time Factors
D000336:Aerosols; D009113:Muramidase; D016284:Technetium Tc 99m Pentetate